Related Experiment Videos
Calcium channel antagonists. Part V: Second-generation agents
1Department of Medicine, University of Cape Town, Medical School, Observatory, Republic of South Africa.
Cardiovascular Drugs and Therapy
|July 1, 1988
Summary
Second-generation calcium channel blockers offer improved options for cardiovascular treatment. The focus is on developing longer-acting and more vascularly selective agents for better patient outcomes.
Area of Science:
- Pharmacology
- Cardiovascular Medicine
Background:
- Calcium channel blockers (CCBs) are crucial in managing cardiovascular diseases.
- Existing CCBs have limitations in duration of action and selectivity.
Purpose of the Study:
- To review second-generation CCBs and novel formulations.
- To identify agents with enhanced pharmacokinetic and pharmacodynamic profiles.
Main Methods:
- Literature review of dihydropyridines, verapamil-like agents, and diphenylalkylamines.
- Analysis of new slow-release formulations of existing CCBs.
Main Results:
- Second-generation dihydropyridines include amlodipine, felodipine, and others.
- Verapamil-like agents and bepridil represent other classes.
- New slow-release formulations of nifedipine, verapamil, and diltiazem are available.
Conclusions:
- Development efforts focus on longer-acting CCBs.
- Higher vascular selectivity is a key goal for improved therapeutic efficacy.